Product information and disease descriptionPlace of product in therapyApproaches to treatment
Heterogeneity of treatment effect
2 evidence topics · 2 sources
EPICS-III: subgroup defined by baseline ALP
| Subgroup or outcome | Quoted value |
|---|---|
| Baseline ALP threshold | “≤ 3 x ULN” |
| Saroglitazar biochemical response | “83.1%” |
| Placebo biochemical response | “14.7%” |